武汉永璨生物科技有限公司
+86-17702719238 sales@sun-shinechem.com

LP-184

编号: 24121
Cas号: 924835-67-6
纯度: 98% Min.

 LP-184 is an acylfulvene-derived prodrug activated by the oxidoreductase PTGR1 that alkylates at N3-adenine. Cytotoxicity of LP-184 is solely dependent on prostaglandin reductase 1 (PTGR1). LP-184 metabolizes to an active compound by the oxidoreductase activity of enzyme prostaglandin reductase 1 (PTGR1), which is frequently elevated in multiple solid tumor types.


仅供研究使用。 我们不向患者出售。

化学信息

名称 LP-184
Iupac 化学名称 (R)-1-hydroxy-1-((6'-hydroxy-2',4',6'-trimethyl-7'-oxo-6',7'-dihydrospiro[cyclopropane-1,5'-inden]-3'-yl)methyl)urea
同义词LP-184; LP184; LP 184;
英文同义词LP-184; LP184; LP 184;
分子式C16H20N2O4
分子量304.34
SmileCC1=C(CN(O)C(N)=O)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1
InChiKeyVWMPVAZEBAKLFR-HNNXBMFYSA-N
InChiInChI=1S/C16H20N2O4/c1-8-6-10-12(11(8)7-18(22)14(17)20)9(2)16(4-5-16)15(3,21)13(10)19/h6,21-22H,4-5,7H2,1-3H3,(H2,17,20)/t15-/m0/s1
Cas号924835-67-6
相关CAS号

订购信息

包装价格库存纯度备货期
大货询价询价询价
Request Bulk Quote Download MSDS 电话 : +86-177 0271 9238   Email : sales@sun-shinechem.com
外观性状类白色固体
纯度98% Min.
存储 0-4℃,可保存几天到几周;-20℃,可保存 几个月。
可溶性溶于DMSO等有机溶剂
处理方式
运输条件可以在室温下进行运输。
海关编码
Coming soon.
Targets
Mechanism
Cell study
Animal study
Clinical study

1: Lal B, Kulkarni A, McDermott J, Rais R, Alt J, Wu Y, Lopez-Bertoni H, Sall S, Kathad U, Zhou J, Slusher BS, Bhatia K, Laterra J. Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma. Clin Cancer Res. 2023 Oct 13;29(20):4209-4218. doi: 10.1158/1078-0432.CCR-23-0673. PMID: 37494541.


2: Restifo D, McDermott JR, Cvetkovic D, Dos Santos T, Ogier C, Surumbayeva A, Handorf EA, Schimke C, Ma C, Cai KQ, Olszanski AJ, Kathad U, Bhatia K, Sharma P, Kulkarni A, Astsaturov I. Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies. Mol Cancer Ther. 2023 Oct 2;22(10):1182-1190. doi: 10.1158/1535-7163.MCT-22-0818. PMID: 37552607; PMCID: PMC10592171.


3: Kulkarni A, Zhou J, Biyani N, Kathad U, Banerjee PP, Srivastava S, Prucsi Z, Solarczyk K, Bhatia K, Ewesuedo RB, Sharma P. LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency. Cancer Res Commun. 2024 May 6;4(5):1199-1210. doi: 10.1158/2767-9764.CRC-23-0554. PMID: 38630886; PMCID: PMC11072798.


4: Kulkarni A, McDermott JR, Kathad U, Modali R, Richard JP, Sharma P, Bhatia K. The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations. Oncotarget. 2021 Apr 13;12(8):791-806. doi: 10.18632/oncotarget.27943. PMID: 33889302; PMCID: PMC8057270.


5: Kathad U, Kulkarni A, McDermott JR, Wegner J, Carr P, Biyani N, Modali R, Richard JP, Sharma P, Bhatia K. A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications. BMC Bioinformatics. 2021 Mar 2;22(1):102. doi: 10.1186/s12859-021-04040-8. PMID: 33653269; PMCID: PMC7923321.


6: Staake MD, Kashinatham A, McMorris TC, Estes LA, Kelner MJ. Hydroxyurea derivatives of irofulven with improved antitumor efficacy. Bioorg Med Chem Lett. 2016 Apr 1;26(7):1836-8. doi: 10.1016/j.bmcl.2016.02.028. Epub 2016 Feb 13. PMID: 26922141.


7: Sung ES, Kim JH. The difference effect of estrogen on muscle tone of medial and lateral thigh muscle during ovulation. J Exerc Rehabil. 2018 Jun 30;14(3):419-423. doi: 10.12965/jer.1836110.055. PMID: 30018928; PMCID: PMC6028216.

化学结构

24121 -  LP-184 | CAS 924835-67-6

快速订购

Change